ETF Fundamental Report for IWM

Validea's fundamental report on the iShares Russell 2000 ETF (IWM), classified as a Mid-Cap Value ETF, reveals its primary factor exposure is to Value (score 63), with significantly lower scores for Quality (7) and Low Volatility (14), and moderate Momentum (36). The ETF's largest sector allocation is Services, with Biotechnology & Drugs as its top industry, providing institutional investors with a clear understanding of its underlying factor biases and portfolio composition.

Analysis

According to Validea's fundamental report, the iShares Russell 2000 ETF (IWM) is primarily a vehicle for gaining exposure to the value factor within the mid-cap segment. The ETF scores a 63 out of 99 for Value, confirming its classification as a Mid-Cap Value ETF. This value orientation, however, is starkly contrasted by its factor profile in other areas; it registers a notably low score for Quality at 7 and for Low Volatility at 14, while its Momentum exposure is moderate at 36. This composition suggests the underlying portfolio consists of companies that are statistically inexpensive but may lack strong profitability, stable earnings, or robust balance sheets. Portfolio construction further reveals that its largest sector allocation is to Services, with a specific concentration in the Biotechnology & Drugs industry, which can contribute to the ETF's higher volatility and lower quality profile.

Key Decisions for Investors

• Investors seeking value exposure in the mid-cap space can utilize IWM, but must be prepared for the associated high volatility and low-quality characteristics inherent in its portfolio, as indicated by its scores of 14 and 7, respectively.
• Given the ETF's very low Quality score, it may be unsuitable for portfolios prioritizing balance sheet strength and consistent profitability, and investors with such mandates should look for alternative small or mid-cap exposures.
• The significant allocation to the Biotechnology & Drugs industry means the ETF's performance is sensitive to sector-specific catalysts and risks; therefore, positions should be managed with an awareness of the biotech industry's cycle and news flow.